¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ligand induced endocytosis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocytosis
    ¼¼Æ÷³»¼·Ãë, ¿£µµ½ÃÅä½Ã½º
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
  • antibiotic-induced
    Ç×»ýÁ¦À¯¹ß-
  • complement-induced
    º¸Ã¼À¯µµ-
  • drug-induced
    ¾à¹°À¯¹ß-
  • drug-induced hemolysis
    ¾à¹°À¯¹ß¿ëÇ÷
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • drug-induced hepatitis
    ¾à¹°À¯¹ß°£¿°
  • drug-induced immune complex
    ¾à¹°À¯¹ß¸é¿ªº¹ÇÕü
  • drug-induced jaundice
    ¾à¹°À¯¹ßȲ´Þ
  • drug-induced purpura
    ¾à¹°À¯¹ßÀÚ»ö¹Ý
  • drug-induced retinopathy
    ¾à¹°À¯¹ß¸Á¸·º´(Áõ)
  • drug-induced rhinitis
    ¾à¹°À¯¹ßÄÚ¿°, ¾à¹°À¯¹ßºñ¿°
  • exercise-induced anaphylaxis
    ¿îµ¿À¯¹ß¾Æ³ªÇʶô½Ã½º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocytosis
    ¼¼Æ÷³»ÀÌÀÔ
  • steroid-induced glaucoma
    ½ºÅ×·ÎÀ̵å³ì³»Àå
  • pregnancy-induced hypertension
    ÀӽŰíÇ÷¾Ð
  • induced
    À¯¹ß-, À¯µµ-
  • induced labor
    À¯µµºÐ¸¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocytosis
    ¼¼Æ÷³»ÀÌÀÔ
  • receptor-ligand interaction
    ¼ö¿ëü¹èÀ§ÀÚ»óÈ£ÀÛ¿ë
  • antibiotic-induced
    Ç×»ýÁ¦À¯µµ-
  • alcohol-induced hypoglycemia
    ¾ËÄÚ¿ÃÀ¯µµÀúÇ÷´ç
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • exercise-induced anaphylaxis
    ¿îµ¿À¯µµ¾Æ³ªÇʶô½Ã½º
  • induced abortion
    À¯¹ßÀ¯»ê, À¯µµÀ¯»ê
  • steroid-induced atrophy
    ½ºÅ×·ÎÀ̵åÀ§Ãà
  • induced spindle burst
    À¯¹ß¹æÃßµ¹¹ßÆÄ
  • complement-induced
    (¢¡complement-mediated) µµ¿òü¸Å°³-
  • drug-induced immune complex
    ¾àÁ¦À¯¹ß¸é¿ªº¹ÇÕü
  • radiation-induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • drug-induced
    ¾à¹°À¯¹ß-, ¾àÁ¦À¯¹ß-
  • drug-induced hemolysis
    ¾àÁ¦À¯¹ß¿ëÇ÷
  • drug-induced hepatitis
    ¾à¹°°£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Ligand-gated channels
    ¸®°£µå°ü¹®(¡­Î¼Ú¦) ÀÌ¿ÂÅë·Î(¡­÷×ÖØ)
  • receptor-ligand interaction
    ¼ö¿ëü-¹èÀ§ÀÚ »óÈ£ÀÛ¿ë
  • Lhermittes syndrome, radiation-induced
    ¹æ»ç¼±À¸·Î À¯¹ßµÈ ·¹¹ÌÅ× ÁõÈıº
  • NIHL [=noise induced hearing loss]
    ¼ÒÀ½¼º ³­Ã»
  • T1 induced dephasing
    T1 À¯µµ Å»À§»ó
  • abactio =induced abortion, abactus venter<³ª>
    ÀΰøÀ¯»ê(ìÑÍïêüß§).
  • antibiotic-induced colitis (AAC)
    Ç×»ýÁ¦À¯¹ß´ëÀå¿°, Ç×»ýÁ¦À¯¹ß¼³»ç
  • artificial hibernation =induced h.
    Àΰøµ¿¸é(¹ý)(¡­ÔÏØùÛö), ¾à¹°µ¿¸é(¹ý).
  • gradient induced phase shift effect
    °æ»ç À¯µµ À§»ó º¯À§ È¿°ú
  • hallucinogen-induced disorder
    ȯ°¢Á¦ À¯¹ß¼ºÀå¾Ö(º´)(ü³ÊÆð¥ë¯Û¡àõî¡äô)
  • hearing loss, noise induced
    ¼ÒÀ½¼º³­Ã»
  • heat induced hemolytic anemia
    ¿­À¯¹ß¼º ¿ëÇ÷¼º ºóÇ÷
  • induced abortion =provoked a.
    À¯¹ßÀ¯»ê(ë¯Û¡êüß§), ÀΰøÀ¯»ê(ìÑÍïêüß§) .
  • induced allergy
    À¯¹ß(¼º)¾Ë·¹¸£±â.
  • induced allergy
    À¯¹ß(¼º)¾Ë·¹¸£±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • ligand
    ¹èÀ§ÀÚ, ¸®°£µå
  • receptor-ligand interaction
    ¼ö¿ëü-¹èÀ§ÀÚ »óÈ£ÀÛ¿ë
  • endocytosis
    ¼¼Æ÷³»ÀÌÀÔ(á¬øàÒ®ì¹ìý)
  • endocytosis
    ¼¼Æ÷³»ÀÌÀÔ.
  • endocytosis
    ¼¼Æ÷³»ÀÌÀÔ
  • endocytosis
    ¼¼Æ÷³»ÀÌÀÔ
  • endocytosis, reverse
    ¼¼Æ÷³» ÀÌÀÔ(Çö»ó), ¿ª
  • abactio =induced abortion, abactus venter<³ª>
    ÀΰøÀ¯»ê(ìÑÍïêüß§).
  • alcohol induced hypoglycemia
    ¾ËÄڿñâÀÎ(¼º) ÀúÇ÷´ç.
  • antibiotic-induced colitis (AAC)
    Ç×»ýÁ¦À¯¹ß´ëÀå¿°, Ç×»ýÁ¦À¯¹ß¼³»ç
  • artificial hibernation =induced h.
    Àΰøµ¿¸é(¹ý)(¡­ÔÏØùÛö), ¾à¹°µ¿¸é(¹ý).
  • complement-induced = complement-mediated
    º¸Ã¼¸Å°³¼º
  • controlled hypotension ; induced hypoten sion
    Á¶ÀýÀúÇ÷¾Ð(ðàï½î¸úìäâ), À¯¹ßÀúÇ÷¾Ð.
  • crystal induced arthritis
    °áÁ¤À¯¹ß¼º °üÀý¿°(¡­ë¯Û¡àõÎ¼ï½æú).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Induced ovulation
    À¯µµ¹è¶õ
    [¿¾ ¿ë¾î] À¯µµ¹è¶õ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • induced malaria
    Á¢Á¾¸»¶ó¸®¾Æ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ligand-induced endocytosis
    ¸®°£µåÀ¯µµ(ë¯Óô) ¼¼Æ÷³»À¯ÀÔ(á¬øàÒ®×µìý)
  • adsorptive endocytosis
    ÈíÂø¼º(ýåó·àõ) ¼¼Æ÷³»ÇÔÀÔ(á¬øàÒ®ùßìý)
  • endocytosis
    ¼¼Æ÷³»ÀÌÀÔ(á¬øàÒ®ì¹ìý)
  • receptor-mediated endocytosis
    ¼ö¿ëü¸Å°³ ¼¼Æ÷³» ÀÌÀÔ(áôé»ô÷ØÚË¿á¬øàÒ®ì¹ìý)
  • hard ligand
    °æ(Ìã)¶óÀ̰£µå
  • ligand
    ¸®°£µå
  • ligand chromatography
    ¸®°£µå Å©·Î¸¶Åä±×·¡ÇÇ
  • ligand-exchange chromatography
    ¸®°£µå±³È¯(Îßüµ) Å©·Î¸¶Åä±×¶óÇÇ
  • ligand field theory
    ¸®°£µåÀå(íÞ) ÀÌ·Ð(ìµÖå)
  • ligand-gated channel
    ¸®°£µå °ü¹®Åë·Î(μڦ÷×ÖØ)
  • ligand-receptor internalization
    ¸®°£µå-¼ö¿ëü(áôé»ô÷) ³»ÀÔ(Ò®ìý)
  • monodentate ligand
    ÇÑÀÚ¸®¸®°£µå
  • soft ligand
    ¿¬(æã)¸®°£µå
  • aldosterone-induced protein
    ¾Ëµµ½ºÅ×·ÐÀ¯µµ ´Ü¹éÁú(ë¯ÓôÓ±ÛÜòõ)
  • dipole-induced dipole interaction
    ½Ö±ØÀÚÀ¯µµ ½Ö±ØÀÚ »óÈ£ÀÛ¿ë(äªÐ¿í­ë¯ÓôäªÐ¿í­ßÓû»íÂéÄ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gradient induced phase shift effect
    °æ»çÀ¯µµ À§»óº¯À§È¿°ú
  • induced
    À¯µµµÈ, À¯¹ßµÈ, ÀÀÇÑ
  • radiation induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • T1 induced dephasing
    T1À¯µµÅ»À§»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SIH stimulation-induced hypalgesia; stress-induced hyperthermia; suction-induced hypoxemia
CLD chloride diarrhea; chronic liver disease; chronic lung disease; congenital limb deficiency; crystal ...
MLC minimum lethal concentration; mixed leukocyte culture; mixed ligand chelate; mixed lymphocyte concen...
MLCT metal-to-ligand charge transfer
DIT deferoxamine infusion test; diet-induced thermogenesis; diiodotyrosine; drug-induced thrombocytopeni...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RME Receptor-mediated endocytosis
LIBS Ligand-induced binding sites
APO2L AP02 ligand
CD30L CD30 ligand
CD40L CD40 Ligand
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • endocytosis
    ¼¼Æ÷³» ÀÌÀÔ
    ¼¼Æ÷°¡ ±×ÀÇ ¸·À» ħÅõÇÏÁö ¸øÇÏ´Â Å« ºÐÀÚ¸¦ ¼·ÃëÇÏ´Â °Í. ½Ä ÀÛ¿ë°ú À½ ÀÛ¿ë, ¾ç ÀÛ¿ëÀÌ ¸ðµÎ Æ÷ÇԵȴÙ.
  • endogenous ligand
    ³»Àμº ¹èÀ§ÀÚ
  • ligand receptor binding
    ¸®°£µå ¼ö¿ë±â °áÇÕ
  • bullous drug-induced exanthema
    ¾à¹°¿¡ ÀÇÇÑ ¼öÆ÷¼º ¹ßÁø
  • denture-induced hyperplasia
    ÀÇÄ¡¼º À°¾ÆÁ¾
    ?
  • drug induced
    ¾à¹° À¯¹ß¼º
  • drug induced disorder
    ¾à¹° À¯¹ß¼º Áúȯ
  • drug-induced
    ¾à¹° À¯¹ß¼º
  • drug-induced allergic hepatopathy
    ¾à¹° ¾Ë·¹¸£±â¼º °£º´Áõ, ¾à¹° À¯¹ß ¾Ë·¹¸£±â¼º °£º´Áõ
  • drug-induced autoantibody
    ¾à¹° À¯Àμº ÀÚ°¡ Ç×ü
  • drug-induced cholestais
    ¾àÁ¦¼º ´ãÁó ¿ïü
  • drug-induced enanthema
    ¾à¹° À¯µµ¼º Á¡¸·Áø
  • drug-induced hemolytic anemia
    ¾à¹°¼º ¿ëÇ÷¼º ºóÇ÷, ¾àÁ¦ À¯¹ß¼º ¿ëÇ÷¼º ºóÇ÷
  • drug-induced immune complex
    ¾àÁ¦ À¯¹ß¼º ¸é¿ª º¹ÇÕü
  • drug-induced leukopenia
    ¾à¹°¼º ¹éÇ÷±¸ °¨¼ÒÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
ligand induced endocytosis The formation of coated pits and then coated vesicles as a consequence of the interaction of ligand with receptors, which then interact with clathrin and associated proteins (coatomers) on the cytoplasmic face of the plasma membrane and come together to form a pit. Not all coated vesicle uptake of receptors requires receptor occupancy.
(18 Nov 1997)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
receptor mediated endocytosis Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route.
(18 Nov 1997)
endocytosis Uptake of material into a cell by the formation of a membrane bound vesicle.
(18 Nov 1997)
ambident ligand <chemistry> A ligand that can donate electrons through two or more atoms on their molecule.
(05 Feb 1998)
cyanocobalamin beta-ligand transferase <enzyme> Cytosolic enzyme utilizing fad, NADPH and reduced glutathione; forms glutathionylcobalamin from cyanocobalamin
Registry number: EC 2.5.1.-
Synonym: ccbl transferase
(26 Jun 1999)
ELAM-1 ligand fucosyltransferase <enzyme> Directs the expression of an elam-1 ligand; an alpha(1,3) fucosyltransferase
Registry number: EC 2.4.1.-
Synonym: elft protein, elft gene product
(26 Jun 1999)
ligand <chemistry, immunology> Any molecule that binds to another, in normal usage a soluble molecule such as a hormone or neurotransmitter, that binds to a receptor. The decision as to which is the ligand and which the receptor is often a little arbitrary when the broader sense of receptor is used (where there is no implication of transduction of signal). In these cases it is probably a good rule to consider the ligand to be the smaller of the two thus in a lectin sugar interaction, the sugar would be the ligand (even though it is attached to a much larger molecule, recognition is of the saccharide).
(18 Nov 1997)
ligand binding site The site on a protein's surface that binds a ligand; equivalent to the active site if the ligand is the substrate of an enzyme.
(05 Mar 2000)
ligand-gated channel A class of ion channel's whose ionic permeability is regulated by cell membrane receptors that respond to specific extracellular chemical signals.
(05 Mar 2000)
ligand gated ion channel A transmembrane ion channel whose permeability is increased by the binding of a specific ligand, typically a neurotransmitter at a chemical synapse. The permeability change is often drastic, such channels let through effectively no ions when shut, but allow passage at up to 10exp7 ions sexp 1 when a ligand is bound. Recently, the receptors for both acetylcholine and GABA have been found to share considerable sequence homology, implying that there may be a family of structurally related ligand gated ion channels.
(18 Nov 1997)
abnormalities, drug-induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
(12 Dec 1998)
abnormalities, radiation-induced Congenital changes in the morphology of organs produced by exposure to ionizing or non-ionizing radiation.
(12 Dec 1998)
abortion, induced Intentional removal of a foetus from the uterus by any of a number of techniques. (popline, 1978)
(12 Dec 1998)
akathisia, drug-induced Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation).
(12 Dec 1998)
alpha-chymotrypsin-induced glaucoma Transient secondary glaucoma following the use of alpha-chymotrypsin in cataract extraction.
(05 Mar 2000)
antibiotic induced enteritis <pathology> A condition where the normal intestinal bacteria (useful for digestion) are killed by the use of an antibiotic resulting in symptoms.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocytosis
    (»ý)¼¼Æ÷ À̹° Èí¼ö
  • induced drag
    (°ø)À¯µµÇ×·Â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á